In the IMMEDIATE (Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care) Trial [ 8 ], participants with suspected ACS who received intravenous glucose-insulin-potassium (GIK) had generally fewer serious outcomes at 1 year than those treated with placebo, but the difference did not reach statistical significance [ 9 ].
← all excerpts
In-hospital measurement of left ventricular ejection fraction and one-year outcomes in acute coronary syndromes: results from the IMMEDIATE Trial.
1
—
—